Evidence map›Paper›PMID 25028599›Full record

ArticleJournal of ovarian research2014

KIFCI, a novel putative prognostic biomarker for ovarian adenocarcinomas: delineating protein interaction networks and signaling circuitries.

Shrikant Pawar, Shashikiran Donthamsetty, Vaishali Pannu, Padmashree Rida, Angela Ogden, Nathan Bowen, Remus Osan, Guilherme Cantuaria, Ritu Aneja

Open access · goldAbstract read
In one paragraph

Article in Journal of ovarian research, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed, 1 pooled it
1.5field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

33 citing papers in PubMed, 1 synthesis or guideline pooled it, 53 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. High Expression of KIFC1 in Glioma Correlates with Poor Prognosis.Journal of Korean Neurosurgical Society · 2024
    Article
  6. Review
  7. Role of motor proteins in human cancers.Saudi journal of biological sciences · 2022
    Review
  8. Article
  9. Article
  10. High KIFC1 expression is associated with poor prognosis in prostate cancer.Medical oncology (Northwood, London, England) · 2021
    Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Shrikant PawarDepartment of Biology, Georgia State University, Atlanta, GA 30303, USA.
Shashikiran DonthamsettyDepartment of Biology, Georgia State University, Atlanta, GA 30303, USA.
Vaishali PannuDepartment of Biology, Georgia State University, Atlanta, GA 30303, USA.
Padmashree RidaDepartment of Biology, Georgia State University, Atlanta, GA 30303, USA.
Angela OgdenDepartment of Biology, Georgia State University, Atlanta, GA 30303, USA.
Nathan BowenCenter for Cancer Research and Therapeutic Development (CCRTD), Clark Atlanta University, Atlanta, GA 30314, USA.
Remus OsanDepartment of Mathematics and Statistics, Georgia State University, Atlanta, GA 30303, USA.
Guilherme CantuariaNorthside Hospital Cancer Institute, Atlanta, GA 30342, USA.
Ritu AnejaDepartment of Biology, Georgia State University, Atlanta, GA 30303, USA.
Georgia State University · USClark Atlanta University · USNorthside Hospital · US

Funding

Evaluation of HSET as a Novel Theranostic Target for Breast Cancer TherapyR01CA169127 · NCI · GEORGIA STATE UNIVERSITY · PI ANEJA, RITU · 2012 to 2016
$1.7M
Evaluation of antiangiogenic role of EM011, a novel tubulin-binding agentR00CA131489 · NCI · GEORGIA STATE UNIVERSITY · PI ANEJA, RITU · 2010 to 2012
$732k
NCI NIH HHS R00CA131489NCI NIH HHS R01 CA169127
6 · The paper itself

Abstract

backgroundAmplified centrosomes in cancers are recently garnering a lot of attention as an emerging hub of diagnostic, prognostic and therapeutic targets. Ovarian adenocarcinomas commonly harbor supernumerary centrosomes that drive chromosomal instability. A centrosome clustering molecule, KIFC1, is indispensable for the viability of extra centrosome-bearing cancer cells, and may underlie progression of ovarian cancers.

methodsCentrosome amplification in low- and high- grade serous ovarian adenocarcinomas was quantitated employing confocal imaging. KIFC1 expression was analyzed in ovarian tumors using publically-available databases. Associated grade, stage and clinical information from these databases were plotted for KIFC1 gene expression values. Furthermore, interactions and functional annotation of KIFC1 and its highly correlated genes were studied using DAVID and STRING 9.1.

resultsClinical specimens of ovarian cancers display robust centrosome amplification and deploy centrosome clustering to execute an error-prone mitosis to enable karyotypic heterogeneity that fosters tumor progression and aggressiveness. Our in silico analyses showed KIFC1 overexpression in human ovarian tumors (n = 1090) and its upregulation associated with tumor aggressiveness utilizing publically-available gene expression databases. KIFC1 expression correlated with advanced tumor grade and stage. Dichotomization of KIFC1 levels revealed a significantly lower overall survival time for patients in high KIFC1 group. Intriguingly, in a matched-cohort of primary (n = 7) and metastatic (n = 7) ovarian samples, no significant differences in KIFC1 expression were detectable, suggesting that high KIFC1 expression may serve as a marker of metastases onset. Nonetheless, KIFC1 levels in both primary and matched metastatic sites were significantly higher compared to normal tissue . Ingenuity based network prediction algorithms combined with pre-established protein interaction networks uncovered several novel cell-cycle related partner genes on the basis of interconnectivity, illuminating the centrosome clustering independent agenda of KIFC1 in ovarian tumor progression.

conclusionsOvarian cancers display amplified centrosomes, a feature of aggressive tumors. To cope up with the abnormal centrosomal load, ovarian cancer cells upregulate genes like KIFC1 that are known to induce centrosome clustering. Our data underscore KIFC1 as a putative biomarker that predicts worse prognosis, poor overall survival and may serve as a potential marker of onset of metastatic dissemination in ovarian cancer patients.

Indexed as

AdenocarcinomaAdultAgedAge FactorsBiomarkers, TumorCarcinoma, Ovarian EpithelialCentrosomeCluster AnalysisFemaleGene ExpressionGene Expression ProfilingHumansKinesinsMiddle AgedMitosisNeoplasm GradingBiomarkers, TumorKIFC1 protein, humanKinesins

Identifiers

PMID25028599
PMCPMC4098650
OpenAlexW2153067045

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.